Sonova Holding AG (SONVY) AI Stock Analysis

• Market Cap: $15.77B
• Dividend Yield: 1.98%
• Average Volume (3M): 3.58K
• Price to Earnings (P/E): 26.8
• Beta (1Y): 0.77
• Revenue Growth: 6.46%
• EPS Growth: -10.22%
• Country: US
• Employees: 18,335
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 1.71
• Shares Outstanding: 298,134,030
• 10 Day Avg. Volume: 2,397
• 30 Day Avg. Volume: 3,581
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.18
• Enterprise Value/Revenue: 5.12
• Enterprise Value/Gross Profit: 7.16
• Enterprise Value/Ebitda: 22.36
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 73 Outperform
• Price Target: $63.00 ▲(15.01% Upside)

Sonova Holding AG exhibits strong financial performance with consistent revenue and profit growth, effective cost management, and robust cash flow generation. The technical indicators suggest a neutral to slightly bearish trend, while the valuation indicates a moderately priced stock with a modest dividend yield. The absence of earnings call and corporate events data does not impact the score.

Sonova Holding AG Business Overview & Revenue Model

Company Description

Sonova Holding AG designs, develops, manufactures, and distributes hearing care solutions for adults and children. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The company offers wireless communication products; rechargeable hearing aids; wireless headsets, speech enhanced hearables, audiophile headphones, microphones, and wireless transmission systems; and audiological care services. It also provides hearing instruments under the Phonak, Unitron, and Hansaton brand names; cochlear implants under the Advanced Bionics brand; consumer hearing products under the Sennheiser brand; and audiological care services under the AudioNova, Audium, Audition Santé, Boots Hearingcare, Connect Hearing, Geers, Hansaton, Lapperre, Schoonenberg, and Triton brands. The company sells its products through independent distributors; and provides hearing care services through a network of approximately 3,600 stores and clinics. It operates in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. Sonova Holding AG was founded in 1947 and is headquartered in Stäfa, Switzerland.

How the Company Makes Money

Sonova makes money primarily through the sale of hearing aids and related products, which account for a significant portion of its revenue. The company generates income by selling its devices directly to consumers as well as through partnerships with audiologists and hearing care professionals who provide fitting and aftercare services. Additionally, Sonova earns revenue from its cochlear implant segment, which includes advanced solutions for severe hearing loss. The company also benefits from ongoing service contracts and accessories that enhance the user experience. Strategic partnerships with healthcare providers, clinics, and distributors further amplify its reach and revenue potential. Furthermore, Sonova invests in research and development to innovate and expand its product offerings, helping to maintain a competitive advantage in the market.

Sonova Holding AG Financial Statement Overview

Summary

Sonova Holding AG demonstrates strong financial performance with consistent revenue and profit growth, effective cost management, and robust cash flow generation. The company maintains a stable capital structure with low leverage, though slight increases in liabilities should be monitored.

Income Statement

Sonova Holding AG demonstrates strong profitability with a consistent gross profit margin of approximately 72% and a solid net profit margin of 14% for the latest fiscal year. The company has shown a stable revenue growth rate of 7% from the previous year, indicating healthy business expansion. The EBIT margin stands at 18%, and the EBITDA margin is at 24%, both reflecting effective cost management and operational efficiency.

Balance Sheet

The balance sheet of Sonova Holding AG shows a robust equity ratio of 45%, highlighting a stable capital structure. The debt-to-equity ratio is relatively low at 0.66, indicating manageable leverage levels. Return on equity is strong at 20%, showcasing effective utilization of shareholder funds. However, the total liabilities have slightly increased, which requires monitoring.

Cash Flow

Cash flow analysis reveals a healthy operating cash flow to net income ratio of 1.47, suggesting strong cash generation relative to net earnings. The free cash flow has grown by 5% compared to the previous year, and the free cash flow to net income ratio is 1.21, indicating efficient cash management and sufficient free cash flow for reinvestment or debt reduction.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	3.63B	3.87B	3.63B	3.74B	3.36B	2.60B
Gross Profit	2.59B	2.78B	2.62B	2.59B	2.42B	1.84B
EBITDA	830.40M	927.00M	921.70M	978.70M	960.90M	755.30M
Net Income	601.00M	540.50M	601.00M	647.50M	649.00M	581.00M
Balance Sheet
Total Assets	5.79B	5.92B	5.79B	5.55B	5.59B	5.93B
Cash, Cash Equivalents and Short-Term Investments	513.80M	687.10M	513.80M	414.80M	612.00M	1.77B
Total Debt	1.79B	1.76B	1.79B	1.81B	1.48B	1.83B
Total Liabilities	3.30B	3.24B	3.30B	3.32B	3.16B	3.15B
Stockholders Equity	2.47B	2.66B	2.47B	2.21B	2.41B	2.75B
Cash Flow
Free Cash Flow	663.50M	656.10M	624.70M	609.10M	815.90M	665.50M
Operating Cash Flow	748.80M	793.70M	753.30M	763.40M	922.50M	754.70M
Investing Cash Flow	-235.70M	-212.70M	-234.00M	-429.50M	-707.00M	-123.60M
Financing Cash Flow	-409.10M	-401.80M	-415.30M	-523.50M	-1.37B	687.60M

Sonova Holding AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 54.78
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SONVY, the sentiment is Negative. The current price of 54.78 is below the 20-day moving average (MA) of 55.72, below the 50-day MA of 57.10, and below the 200-day MA of 60.02, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 41.28 is Neutral, neither overbought nor oversold. The STOCH value of 30.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SONVY.

Sonova Holding AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZBH	―	$19.72B	24.28	6.52%	0.96%	4.11%	-14.43%
SONVY	―	$15.77B	26.82	21.18%	1.98%	6.46%	-10.22%
SNN	―	$15.24B	31.65	9.20%	2.10%	5.78%	61.52%
STE	―	$23.26B	35.90	9.73%	0.99%	2.47%	63.68%
PODD	―	$21.96B	94.94	19.18%	―	25.99%	-40.46%
PHG	―	$26.09B	―	―	3.25%	-0.76%	-55.03%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Sonova Holding AG Corporate Events

Sonova’s Latest Study on Hearing Instruments: Potential Market Impact

Sonova Holding AG is currently recruiting participants for a clinical study titled Speech Understanding and Listening Effort Benefits of Infinio Sphere. The study aims to explore the benefits of using hearing instruments in adults with bilateral hearing loss, focusing on improvements in speech understanding and listening effort. This research is significant as it seeks to enhance the quality of life for individuals with hearing impairments by identifying the most effective hearing aid models.

Sonova’s New Study on Extended Wear Hearing Aids: What Investors Need to Know

Sonova Holding AG has announced a new clinical study titled ‘Evaluation of Extended Wear Hearing Aid for Mild Hearing Loss.’ The study aims to assess the benefits of extended wear hearing aids in reducing subjective listening effort in adults with mild sensorineural hearing loss. This research is significant as it could lead to improved hearing solutions for those with mild hearing impairments.

Sonova’s New Hearing Aid Study: A Game Changer for Hearing Technology?

Study Overview: Sonova Holding AG is launching a clinical trial titled ‘Evaluation of Investigational Hearing Instrument Features.’ The study aims to assess how different hearing instrument features perform in various environmental settings for adults with hearing loss. It seeks to determine user preferences for these features, providing significant insights into improving hearing aid technology.